Avalo Therapeutics, Inc. has announced a significant financial maneuver, entering into an Open Market Sale Agreement with Jefferies LLC. This agreement allows the company to offer up to $200 million in common stock through an at-the-market offering program. The move is aimed at enhancing Avalo's financial flexibility and supporting its ongoing operations in the competitive pharmaceutical preparations sector.

The agreement, effective November 5, 2026, permits Avalo to sell shares at its discretion, utilizing Jefferies to manage the sales process. This strategic decision comes as Avalo seeks to optimize its capital structure and funding capabilities.

Background

Avalo Therapeutics, Inc. is a Delaware-based company focused on developing innovative therapies in the pharmaceutical preparations industry, classified under SIC 2834. The company trades on the Nasdaq under the ticker symbol AVTX. Recent filings include a 10-Q and an S-3ASR, both submitted on the same day as this announcement, indicating active engagement with investors and regulatory compliance.

What the Filing Says

According to the filing, "The Company may issue and sell, from time to time at the Company’s sole discretion, shares of the Company’s common stock... through Jefferies." The agreement stipulates that Jefferies will earn a commission of up to 3% of the gross proceeds from any shares sold.

Impact

This new sales agreement could significantly affect Avalo's financial standing, providing necessary capital for research and development initiatives. The termination of the previous sales agreement with TD Cowen, acknowledged in the same filing, allows for a more focused approach to capital raising without the constraints of the earlier arrangement.

What's Next

The filing does not specify what happens next, but the company is likely to proceed with the offering as it seeks to enhance its liquidity and support its operational goals.